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. Therefore, a great deal of research has focused on cellular processes that can contribute to or that can counteract genomic instability. Although the importance of genetic changes in driving cancer has been appreciated for almost 100 years, recent technological advances have substantially increased our ability to study cancer-associated mutations. Furthermore, by studying DNA repair pathways that normally suppress the genomic instability that leads to mutation, we now better understand why mutations arise, and in several cases how we can manipulate cells to reduce the rate of mutation.
In this Review we focus on how translocations arise, with a particular emphasis on how non-homologous endjoining (NHEJ) causes the appearance of many chromosome rearrangements, including the spectacularly complex chromosome translocations that are associated with chromothrypsis
.
The nature of translocations A translocation is an abnormal chromosome region that contains rearranged genetic material, usually from two non-homologous chromosomes Translocations are not exclusive to cancer cells; screening of cells from developing embryos has revealed that substantial numbers of embryos (in the order of 0.7 per 1,000 live births) have cells that contain translocations 3, 4 . Although in some cases these de novo translocations are associated with developmental abnormalities, many balanced translocations do not cause noticeable pathology, suggesting that balanced translocations are well tolerated in many instances. Untransformed primary mouse blood cells also contain a wide range of chromosomal translocations [5] [6] [7] [8] . However, translocations are particularly common in cancer cells. Many translocations have been catalogued 9, 10 and are listed in databases such as the Database of Chromosome Rearrangements in Disease (dbCRID) and the Catalogue of Somatic Mutations in Cancer (COSMIC). Some translocations fuse genetic elements from different genomic locations to form pathological gene fusions that deregulate cell growth, such as the breakpoint cluster region-Abelson tyrosine-protein kinase 1 (BCR-ABL1) translocation in chronic myeloid leukaemia. Historically, most of these gene fusions were found in haematological malignancies; however, a growing number of such mutations have been found in solid tumours 9 . This is exemplified by prostate cancer, in which at least 40% of cases feature translocations between transmembrane protease, serine 2 (TMPRSS2) and a gene encoding the ETS transcription factor, ERG 11 . The frequency of recurrent gene fusions varies depending on the specific type of cancer, but currently known translocations are estimated to drive ~20% of cancer cases 9 . Next-generation sequencing of genomes and transcriptomes from primary human cancer cells is revealing new gene fusions that may be involved in driving tumorigenesis, including new examples found in colorectal carcinoma, breast cancer and acute lymphoblastic leukaemia (ALL) [12] [13] [14] . Nonetheless, sequencing has shown that somatic mutations affecting the sequence of genes are considerably more common than chromosome rearrangements [12] [13] [14] [15] [16] [17] . Sequencing efforts have also revealed that cancer genomes do not typically contain a discrete number of coherent reciprocal translocations. Tumour cells more commonly contain a large number of complex translocations, featuring interchromosomal and intrachromosomal Break-induced replication (BIR) . A modified homology-based repair pathway in which a broken DNA end is repaired by copying a large amount of sequence from an undamaged homologous partner, potentially leading to copying of the entire homologous sequence from the site of damage to the end of the chromosome.
rearrangements (FIG. 1) . In most cases, it is not possible to draw definite conclusions about the mechanism or extent by which any one of these individual translocations contributes to the malignancy of the cancer cell. Furthermore, the frequency and the type of translocations are not always shared among tumours of the same class. Sequence data from primary breast cancers showed between zero and 29 translocations per case 13 . Squamous cell lung cancer cells have a higher rate of translocations, with an average of 165 somatic rearrangements per cell, compared with 98 rearrangements per cell in non-small cell lung carcinoma and 90 rearrangements per genome in prostate tumours [15] [16] [17] . Rearrangements in cancer cells affect genic and non-genic DNA at approximately equal rates; however, a study in prostate cancer cells found an enrichment of rearrangements in transcribed regions, as measured by RNA polymerase II chromatin immunoprecipitation (ChIP) 15 . A study in breast cancer cells also reported an increased rate of rearrangements within the total area (including introns) of protein-coding genes 13 . A minority of translocations form gene fusion events, but translocations may also contribute to tumorigenesis by interrupting the sequence of tumour suppressor genes, as observed for the tumour suppressor tetratricopeptide repeat domain 28 (TTC28) in certain cases of colorectal carcinoma 12 . As is the case with mutations affecting gene sequence, many translocations seen in cancer cells are probably bystander mutations as opposed to drivers of the disease. The number of translocations in tumour cells from a cohort of patients with lung adenocarcinoma was not found to correlate with clinical outcome 17 . Hence, tumours with a small number of translocations can be more aggressive and more difficult to treat than tumours with many translocations. Other types of mutations in addition to translocations clearly play an important part in driving the growth and survival of cancer cells.
The frequency and complexity of cancer-associated translocations has required the development of new bioinformatic tools to analyse and display the huge volume of data that is being generated by cancer genomesequencing projects 18 (FIG. 1 ). An example of a spectacular genomic rearrangement was revealed in a case of chronic myeloid leukaemia (CML) that had 42 intrachromosomal rearrangements affecting chromosome 4q 19 . Such highly complex, clustered translocations are referred to as chromothrypsis. These rearrangements can affect one or more chromosomes in a cell and are thought to be generated in a single catastrophic event. An initial estimate indicates that as many as 3% of all cancers exhibit such clustered rearrangements 20 . It is plausible that the same mechanisms that cause chromothrypsis also cause the complex translocations seen in other cancer cells 2 . Complex translocations similar to chromothrypsis have been described as a result of sequencing the genomes of cells from prostate cancer and ALL 14, 21 .
NHEJ as a source of genomic instability Several pathways have been proposed to be involved in the formation of translocations 22 (FIG. 2) . These pathways include NHEJ, breakage-fusion-bridge cycles
3) and replication-based mechanisms, such as breakinduced replication (BIR) 23 . Replication-based mechanisms are proposed to cause translocations by switching the extending DNA strand from its template sequence to
Key points
• Translocations that create neomorphic fusion genes occur in both lymphoid malignancies and solid tumours.
• A large number of translocations do not encode fusion genes and may not contribute to malignancy. • Translocations frequently contain complex, clustered sequence rearrangements, similar to chromothrypsis, and may also contain genetic material from several different chromosomes.
• Many translocations arise as a consequence of 'classical' or 'alternative' pathways of non-homologous end-joining.
• Mammalian cells have regulatory systems to bias DNA repair towards repair pathways that are less likely to contribute to translocation.
• Frequency of DNA breakage is the metric that best predicts the likelihood of a particular genomic site being involved in a translocation.
• Therapeutic intervention to reduce translocation frequency is a potential mechanism for reducing the risk of cancer.
Box 1 | Types of chromosomal translocations
The development of techniques for visualizing and staining chromosomes using dyes such as quinacrine and Giemsa led to the first identification of translocations in the 1950s, and important disease-causing rearrangements are still being discovered today. A chromosome that contains a translocation is termed a 'derivative chromosome', and the nature of the rearrangements that affect that chromosome are described by a systematic nomenclature. Robertsonian translocations are those in which the long arms of two acrocentric chromosomes are joined around a single centromeric region.
Reciprocal translocations describe the exchange of genetic material between two chromosome arms. Such translocations can be classified as 'balanced' or 'unbalanced' depending on whether the translocation affects the copy number of any section of the genome, with a balanced translocation causing no change to overall copy number. Many well-known pathological translocations fall into the class of apparently balanced, reciprocal translocations between two non-homologous chromosomes. This group includes the Philadelphia chromosome, t(9;22) (translocation between chromosome 9 and 22) found in chronic myeloid leukaemia; a translocation between chromosomes 11 and 22, t (11;22) , which is seen in 85% of cases of Ewing's sarcoma; and a translocation of chromosomes 8 and 14, t(8;14) , which is seen in 85% of cases of Burkitt's lymphoma. Translocations such as these promote cancer by deregulating the expression of key cellular transcription factors and signalling modulators to cause uncontrolled growth. In addition to the recurrent t(9;22) translocation in chronic myeloid leukaemia, which causes overexpression of ABL1 kinase, the t(11;22) translocation in Ewing's sarcoma causes deregulated activity of Friend leukaemia integration 1 (FLI1), an ETS transcription factor, whereas t(8;14) in Burkitt's lymphoma is a translocation that causes the overexpression of the mitogenic MYC transcription factor. another homologous template during DNA replication, potentially resulting in a non-homologous sequence being copied into the new DNA strand 24, 25 . However, in the absence of an appropriate inducible model or genetic evidence for the requirement of specific factors in mediating replication-based translocations, it is challenging to quantify the contribution of such pathways to the overall frequency of translocations. Mechanisms based on homologous recombination may also cause translocations, such as non-allelic homologous recombination (NAHR), which has been implicated in chromosome rearrangements that occur in the germ line 26 . Translocations, in particular those translocations that generate gene fusions, are often assumed to form because of the joining of DNA double-strand breaks that arise at different sites on non-homologous chromosomes. In this case, the double-strand breaks are joined by an endogenous DNA repair pathway such as NHEJ (FIG. 4) . In mammalian cells, the best-characterized pathway for NHEJ, which has become known as 'classical' NHEJ (C-NHEJ), initiates through the binding of a heterodimer comprised of Ku70 (also known as XRCC6) and Ku80 (also known as XRCC5) to broken DNA ends 27 . A complex of DNA-dependent protein kinase catalytic subunit (DNA-PKcs; also known as PRKDC) and Artemis (also known as DCLRE1C) subsequently binds to the Ku70-Ku80-DNA complex and processes the DNA end through the nuclease activity of Artemis. Finally, a complex comprised of XRCC4-like factor (XLF; also known as NHEJ1), XRCC4 and DNA ligase 4 (LIG4) joins the DNA ends (FIG. 4) . The importance of the NHEJ pathway in maintaining genomic stability is known from genetic studies in mice [28] [29] [30] and from individuals with mutations in key NHEJ genes (TABLE 1) .
Despite the appearance of chromosomal translocations in cells that lack NHEJ activity, several lines of evidence suggest that, in certain cases, NHEJ contributes to the appearance of chromosomal translocations. Deficiency in RAD18 makes cells hypersensitive to camptothecin, an agent that is used in certain chemotherapy regimens on the basis of its ability to cause DNA double-strand breaks. However, this hypersensitivity is relieved by suppressing NHEJ 31 . Mutations in BRCA1, which is required for homologous recombination, or in any of the Fanconi anaemia complementation group (FANC) genes, which excise DNA interstrand crosslinks, predispose affected individuals to cancer owing to the requirement of these factors for normal DNA repair. However, several reports have concluded that ablation of NHEJ factors such as Ku70, Ku80 or LIG4 reduces genomic instability and the appearance of chromosome rearrangements in BRCA1-or FANCdeficient cells [32] [33] [34] [35] . Chemical inhibition of DNA-PKcs has also been reported to reduce genomic instability in cell lines lacking BRCA1 and BRCA2 (REF. 36 ). Collectively, these results suggest that, when mammalian DNA repair pathways are defective, the NHEJ pathway can increase the amount of genomic instability and, therefore, accelerate the accumulation of mutations that contribute to cancer.
Genomic sequencing indicates that up to 50% of ovarian carcinoma cells have mutations that affect the homologous recombination pathway, making these cells particularly vulnerable to aberrant DNA repair by NHEJ 37 . Cells from patients with breast cancer have a higher than expected frequency of mutations in FANCC, Bloom's syndrome, RecQ helicase-like (BLM; also known as RECQL3) and XRCC2 . These genes are essential for error-free repair of DNA damage, hence cells with these mutations may over-use NHEJ for repair, leading to further accumulation of genetic abnormalities. Another form of evidence that NHEJ is important for chromosome translocations has come from the study of the genetic requirements for the fusion of uncapped telomeres
. NHEJ is also considered to be the mechanism that underlies the complex pattern of translocations and rearrangements seen in chromothrypsis 19 . Therefore, NHEJ has an important role in shaping the genome of the cancer cell by contributing to error-prone pathways of DNA repair that lead to the appearance of mutation.
Classical versus alternative end-joining pathways
Early studies on the characteristics of end-joining activities in mammalian cells demonstrated the presence of two classes of products: those formed from the simple ligation of DNA ends and those in which small sections of shared sequence identity (microhomology) at the joined ends could be observed 41, 42 (FIG. 4) . Yeast studies support the importance of Ku70-Ku80 for NHEJ but additionally show that in the absence of these factors an alternative activity can mediate joining using micro homology, although with some deletion of DNA sequence around the break site [43] [44] [45] . Subsequent biochemical data and assays with end-joining substrates with different amounts of terminal homology showed that the joining of ends with 6-8 bp of homology is independent of the Ku-mediated C-NHEJ 46,47 and instead requires a NHEJ pathway called alternative end-joining (A-EJ) or microhomology-mediated end-joining (MMEJ). The existence of A-EJ accounts for translocations and chromosome rearrangements in cells that lack Ku70, Ku80 or LIG4 (REF. 29 ). Notably, mice with targeted knockouts of Ku70 -Ku80, XRCC4 or LIG4 in combination with p53 deficiency develop tumours with translocations featuring microhomology 48, 49 . Microhomology was also reported in 85% of the translocations that were induced using a translocation reporter system in mouse embryonic stem cells 50 . Therefore, A-EJ seems to be capable of producing translocations, particularly when C-NHEJ is deficient. In a system that measured the frequency of translocations between the immunoglobulin heavy chain complex (Igh) and Myc in mouse B cells, deletion of Ku70 or LIG4 actually increased the rate of translocation, with A-EJ apparently providing the joining activity 51 . Translocations were also increased in a reporter system in mouse embryonic stem cells when XRCC4-XLF was inactivated 52 . These results suggest that NHEJ causes a low rate of translocations, but in its absence A-EJ becomes active and produces an increased number of chromosome rearrangements. hypothesized to form as a consequence of the fusion of two double-strand breaks that arise in the same cell. Following the appearance of DNA double-strand breaks, a signalling pathway is activated, which leads to the ligation of the free DNA ends that is mediated by factors of the non-homologous end-joining pathway. Red and blue strands represent different chromosomes, which may become incorrectly joined by endogenous repair pathways. b | Telomere uncapping or attrition generates a DNA double-strand break response, which potentially leads to the fusion of telomeres, generating end-to-end fusions. During anaphase, dicentric fusion chromosomes are pulled apart, leading to the formation of translocations and double-strand breaks. Broken chromosomes act as substrates for additional rounds of fusion and breakage, generating increasingly complex translocations. c | Hypothetically, translocations could arise through a replication-based mechanism by 'switching' of the DNA replication machinery to a site on a different chromosome with some degree of sequence homology to the original template. Extension of the replication fork (short arrows) at a site on a different chromosome (crooked arrow) would lead to a composite daughter strand being produced, which would contain sequence from two chromosomes. This composite chromosome would appear as a translocation. Highly complex translocations could be generated by multiple template switching events, generating an aberrant chromosome that contains sequence from several different parts of the genome.
A-EJ is of particular interest because micro homology signatures have been reported at the breakpoints of chromosome rearrangements in primary human cancer cells 53, 54 . This raises the possibility that A-EJ, or some other microhomology-based mechanism, is responsible for the formation of translocations. The amount of microhomology used in repair of a DNA double-strand break is the standard measure for distinguishing between C-NHEJ and A-EJ, but it is unclear how much microhomology is optimal for each pathway. Understanding the importance of A-EJ in the formation of translocations will require better characterization of the components of the pathway. The identification of factors that are required for A-EJ in mammalian cells has been aided by studies in yeast, which have suggested that factors such as meiotic recombination 11 (Mre11), Rad50 and Sae2 are involved in A-EJ 53 . Studies using translocation reporter constructs in mouse embryonic stem cells have shown that the frequency of translocations between induced double-strand breaks on different chromosomes is reduced after knockdown of CtBP-interacting protein (CtIP; also known as RBBP8), an exonuclease that is considered to be the closest mammalian homologue of Sae2 (REF. 55 ). Furthermore, the translocations that do occur show a reduced amount of microhomology at the breakpoints, supporting a role for CtIP in a pathway that produces translocations using microhomology.
A role for CtIP in A-EJ is plausible according to a model in which limited exonuclease resection of DNA double-strand breaks is necessary to uncover stretches of microhomology that can anneal and mediate joining (FIG. 4) . Intrachromosomal joining assays in mammalian embryonic stem cells and cell lines have likewise supported an involvement of Mre11 in Ku-independent end-joining using microhomology 56, 57 . However, although modulation of end resection seems to be a key regulator of A-EJ, data from mouse B cells measuring induced intrachromosomal rearrangements showed no reduction of microhomology-mediated joining in cells after CtIP knockdown or MRE11 inhibition 58 . Therefore, the essential genetic make-up of A-EJ is an ongoing question in the field, and multiple redundant processes might contribute to A-EJ. The DNA end-binding factor Ku has recently been suggested to have a key regulatory role in suppressing the use of A-EJ, as depletion of human Ku86 was found to increase the use of A-EJ in cells lacking other C-NHEJ factors . In B cells with deficiencies in C-NHEJ, deletion of XRCC1 or knockdown of LIG3 had no effect on translocations between MYC and IGH. The relative importance of LIG3 and LIG1 in A-EJ is thus still somewhat unclear.
Although A-EJ is an important pathway for the formation of translocations, several lines of evidence suggest that C-NHEJ still accounts for most rearrangements. First, the measured amount of microhomology found in translocation reporter cell lines is quite low, with a mean of 1.36 bp 50 . Second, in two different inducible systems that generate experimental interchromosomal translocations, microhomology-mediated joining was observed in a minority of cases 63, 64 . Third, data from next-generation sequencing projects involving human cancer patients indicate a minor role for A-EJ. For example, one recent study used next-generation sequencing technology to characterize the breakpoints of 52 germline chromosomal rearrangements from human patients 65 . Most of these rearrangements were thought to be balanced translocations. However, at the molecular level they almost invariably featured the deletion of genetic sequence at the breakpoint junction. A significant number of the translocations were not formed by the simple joining of DNA breaks but involved local fragmenting of the DNA with the reassembly of inverted local sequence at the final translocation join. Of the 141 breakpoints
Box 2 | Telomeres and translocations
Telomeres normally protect the end of chromosomes, but incipient tumour cells are known to have acutely short telomeres 120, 121 . When telomeres become shortened or uncapped by loss of shelterin, the chromosome end is signalled as a double-strand break 122 . Normally, p53 signalling triggers apoptosis in response to this signal, but in telomerase-null mice in the absence of p53, end-to-end chromosome fusions are observed that correlate with a high frequency of epithelial cancer 123 . End-to-end chromosome fusions cause genomic instability because the different centromeres of the fused chromosome are pulled in opposite directions during cell division eventually causing the fused chromosome to break, generating translocations and new DNA ends that form substrates for additional breakage-fusion-bridge cycles 124 (FIG. 3) . Key intermediates in this process -that is, dicentric chromosomes and anaphase bridges -have been observed in primary human tumours 125 . Complex translocations in B cells with combined genetic deletion of DNA repair genes and p53 also seem to be derived from cycles of breakage-fusion-bridge 48, 49 . These complex translocations feature amplification of the MYC oncogene, which is an essential driver of tumorigenesis in these cells. End-to-end fusion of uncapped telomeres is also dependent on the non-homologous end-joining factors Ku70 and DNA ligase 4 (REFS 126, 127) . Whereas loss of the shelterin component telomeric repeat-binding factor 2 (TRF2) causes chromosome fusion by classical non-homologous end-joining DNA repair pathways 128 , alternative end-joining-mediated chromosome fusions are observed in TRF2-deficient cells when Ku80 is absent. In mice, the shelterin proteins TRF1, tripeptidyl-peptidase 1 (TPP1), protection of telomeres protein 1A (POT1A) and POT1B combine with TRF2 to suppress alternative end-joining events 78, 129 . Although the importance of this effect in human cancer is not fully clear, mouse models of cancer that arises from defective telomere function share many common genomic features with human tumours 130 . Hence, both classical and alternative end-joining pathways are active in causing chromosome rearrangements that arise from end-to-end fusions. identified through next-generation sequencing, just 30.5% had regions of microhomology. In addition, chromosome rearrangements in prostate cancer cells do not usually contain microhomology sequences, and in breast cancer cells microhomology is generally either absent or limited to 2 bp or less 13, 21 . These findings suggest that microhomology-based mechanisms are responsible for a minority of de novo human translocations.
Choice of homologous recombination or NHEJ C-NHEJ is the only double-strand break repair pathway that can join DNA ends with no homology at the repair site. Furthermore, C-NHEJ acts at blunt or minimally processed DNA ends, whereas some degree of resection of the double-strand break is required for homologous recombination, single-strand annealing (SSA) and A-EJ. The regulation of double-strand break resection therefore acts as the key determinant in committing the repair of a double-strand break to C-NHEJ or to a homologybased pathway 66, 67 . One potential method for the regulation of resection is kinetic: resection only proceeds after initial attempts at NHEJ of double-strand breaks have failed. This hypothesis has been supported by multiple lines of evidence using immunofluorescence to detect the accumulation of repair factors at break sites, plasmid rejoining assays and reporter constructs [68] [69] [70] . NHEJ seals DNA breaks with minor nucleotide deletions and additions at the breakpoint and is capable of joining DNA breaks on different chromosomes. It is thus surprising that cells use 'quick and dirty' repair by NHEJ rather than the slower, more accurate repair by homologous recombination. Homologous recombination, which is template-based and much less error-prone than NHEJ, might be expected to be the preferred pathway for the faithful repair of double-strand breaks.
Resection of a DNA double-strand break is initiated by MRE11 as part of a complex with RAD50 and Nijmegen breakage syndrome protein 1 homologue (NBS1) in mammals (the MRN complex) or by Mre11 as part of a complex with Rad50 and Xrs2 in yeast cells (the MRX complex). Resection becomes extensive following the action of CtIP. Exonuclease 1 (EXO1) and BLM-DNA2 have also been reported to generate single-stranded DNA overhangs at break sites in mammalian cells. Cyclindependent kinase (CDK) signalling regulates the activity of the resection apparatus, such that it is mainly active in the S and G2 phases of the cell cycle. Nonetheless, components of the NHEJ pathway remain active in S phase and G2 phase cells and compete with homologous recombination for the repair of double-strand breaks 69, 71 . Extensive resection can also occur in G1, at least in the absence of p53-binding protein 1 (53BP1) and H2AX 72, 73 . Thus, in addition to CDK activity, other levels of regulation must be present to ensure the use of error-free homologous recombination versus mutagenic NHEJ.
The DNA damage response factor 53BP1 is a key regulator of DNA end resection in mammalian cells. 53bp1 −/− cells are mildly sensitive to ionizing radiation compared with other cells with deficiencies in the NHEJ pathway, but 53bp1 −/− B cells have a marked defect in their ability to mediate class switch recombination (CSR) 74, 75 . Several lines of evidence suggest that 53BP1 may act to repress homologous recombination through blocking resection 33, 34, 58, 73, [76] [77] [78] . It is not clear whether 53BP1-mediated blocking of resection achieves the rapid repair of breaks at the expense of potential mutagenicity or whether it has evolved to enable the repair of induced double-strand breaks during the assembly of antigen receptor genes. 53BP1 inhibits the resection of DNA double-strand breaks by recruiting two proteins: Pax transactivation domain-interacting protein (PTIP) and RAP1-interacting factor 1 (RIF1) [79] [80] [81] [82] [83] 131 . PTIP and RIF1 bind to sites in 53BP1 that are phosphorylated by the damage-response kinase ataxia telangiectasia mutated (ATM). 53BP1-RIF1 represses the recruitment of BRCA1 to DNA damage sites in the G1 phase of the cell cycle, with checkpoint defects will continue to grow despite DNA damage signalling, leading to the duplication of the broken chromosome. d | Ligation of broken chromatid ends produces an 'anaphase bridge', with a chromatin connection between the two sister chromatids. e | As chromatids are drawn apart during anaphase, the anaphase bridge is subjected to increasing stress as centromeres are pulled to opposite poles of the dividing nucleus. f | Eventually, the anaphase bridge will shear, producing uneven derivative chromosomes. One derivative chromosome may capture sequence, including a second copy of the oncogene from the broken sister chromatid. The broken chromosomes can act as substrates for further breakage-fusion-bridge cycles (parts b-f), potentially leading to the dramatic amplification of oncogenes near telomeric sites. Oncogene amplification is a driver of malignant cell growth. If breakage-fusion-bridge cycles are combined with the fusion of double-strand breaks from other chromosomes, complex translocations can be built up that feature sequence from multiple chromosomes. whereas BRCA1, in coordination with CtIP, prevents the accumulation of 53BP, RIF1 and PTIP at break sites during S phase and G2 phase (FIG. 5) . In the absence of RIF1, there is a marked defect in CSR, whereas loss of PTIP rescues genome stability in BRCA1-deficient cells. Both RIF1 and PTIP promote end-end fusions of unprotected telomeres. These findings demonstrate the complex regulation of double-strand break repair pathway choice in mammalian cells and reinforce the idea that proper choice is essential for maintaining genome integrity.
DNA-PKcs, which associates with C-NHEJ factors in mammalian cells but which is not present in yeast, is a candidate regulator of NHEJ in mammalian cells. As measured by reporter substrates, increased expression of DNA-PKcs represses homologous recombination, but this effect is not seen with mutant forms of DNA-PKcs that lack kinase activity 84, 85 . Further mutagenesis studies of DNA-PKcs revealed that autophosphorylation of T946, S1004 and T3950 inactivates NHEJ and promotes homologous recombination. Therefore, DNA-PKcs autophosphorylation is likely to be a crucial mechanism for ensuring the appropriate use of homologous recombination. This idea is supported by the observation that mice with targeted substitution of multiple DNA-PKcs autophosphorylation sites die at a very early age and are defective in homologous recombination 86 . Altogether, these findings are consistent with a model in which NHEJ and homologous recombination factors are in active competition for the repair of DNA double-strand breaks. If NHEJ is not initially successful, displacement of NHEJ factors, perhaps by double-strand break resection, might enable error-free repair activities to dominate.
Factors favouring translocations
Experimentally induced double-strand breaks on different chromosomes are known to significantly increase the rate of translocation between those chromosomes 87 . Evidence in favour of a DNA double-strand break intermediate in translocation has come from the study of translocations between the immunoglobulin constant region genes IGKC and IGLC1, as well as MYC in Burkitt's lymphoma. First, double-strand breaks at the IGH locus are known to occur because of the action of the activation-induced cytidine deaminase (AID) enzyme, which deaminates target cytidine residues, leading to the appearance of staggered double-strand breaks 88 . In the absence of AID, translocations between these two genetic loci occur at vanishingly low frequency 89 , demonstrating the importance of double-strand breaks as a substrate for trans location. Experimental systems using site-specific, inducible DNA double-strand breaks have also shown that translocation between two sites is highly dependent on the frequency of double-strand breaks 6, 7 . Further evidence for a doublestrand intermediate leading to translocation came from an analysis of translocation frequency in p53-knockout mice. One activity of the tumour suppressor gene TP53 is On the appearance of a DNA double-strand break, two pathways can be active. Classical non-homologous end-joining (C-NHEJ) involves the binding of Ku70-Ku80 to the DNA break, followed by the recruitment of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and several other factors that mediate blunt-end ligation of the break by DNA ligase 4 (LIG4). This process has no sequence requirements and may cause small-scale mutation, such as the addition or the deletion of a small number of nucleotides at the break junction. Alternative end-joining (A-EJ) involves exonucleolytic processing of the double-strand break to reveal stretches of potentially complementary sequence (microhomology; indicated in red) on either side of the break. This resection process may be mediated by the exonuclease CtBP-interacting protein (CtIP). Following base pairing at regions of microhomology, the ends are joined by an undetermined ligase enzyme (LIG).
to promote apoptosis in cells with double-strand breaks, and deletion of p53 or upstream components of the DNA damage signalling pathway, such as ATM, increases the overall frequency of translocations 90 . This shows that providing an environment that is favourable to DNA double-strand breaks promotes translocation.
The appearance of recurrent translocations, such as IGH-MYC in Burkitt's lymphoma, has posed the question of why certain translocations occur so commonly in specific malignancies. One possibility is that these recurrent translocations arise at no more common a frequency than any other translocation but that they are selected on the basis of their potential to drive survival and proliferation of the cancer cell. An additional, long-standing hypothesis is that recurrent translocations arise because the translocation partners are in particularly close proximity to the nuclei of cells from the affected tissue [91] [92] [93] . Chromosome conformation capture has been used to measure genomic interactions, and combining this technique with deep sequencing has recently enabled the measurement at basepair resolution of how closely genomic loci interact. Using this approach, Hakim et al. 5 showed that IGH and MYC do not interact particularly closely in activated B cells 5 . In fact, even though IGH-MYC translocations are found in 85% of Burkitt's lymphoma, 2,361 other genes interact with IGH more often than MYC. This suggests that nuclear proximity is not the key driver of recurrent, cancer-associated IGH-MYC translocations. Moreover, Rocha et al. 94 showed that there is a poor correlation between genes that physically interact with IGH and those that are AID targets 94 . The authors proposed that AID targets are situated in broader genomic domains that associate with IGH, but the current evidence seems to indicate that physical proximity in the nucleus is a minor determinant of translocation frequency between genes on different chromosomes.
The quantification of how frequently a double-strand break at a specific site forms translocations with other genomic loci has recently become feasible owing to the development of two similar techniques: high-throughput genome-wide translocation sequencing (HTGTS) and translocation-capture sequencing (TC-seq) 6, 7 . These studies were carried out in B cells and focused again on understanding what factors determine the translocation partners of double-strand breaks at IGH or MYC. In both studies, there was a strikingly high correlation between AID target sites and translocation frequency. This suggests that genes that are more often affected by double-strand breaks form translocations more readily. Transcriptional status is another factor that influences translocation frequency, as most translocations were to coding sequences, and transcribed genes were more commonly subject to translocation than were silent genes. Translocation partners for double-strand breaks are not strictly limited to closely interacting chromosome domains, but when a large number of doublestrand breaks is present, there is an increased frequency of interchromosomal translocation between partners with higher physical interaction 95 . All deep-sequencing studies to date have shown that double-strand breaks on the same chromosome, particularly those lying nearby on the same chromosome, have the highest rate of joining, and this matches a previous study of the frequency of joining of breaks induced by the V(D)J recombination-activating protein 1 (RAG1) and RAG2 recombinases 96 . Taking these studies together, the primary predictor for whether genes take part in translocations is the frequency with which those genes undergo doublestrand breakage. Hence, translocations between MYC and IGH are favoured in B cells because those regions are common sites for double-strand breaks in B cells. Active trans cription also correlates with translocation, and up to 40% of translocations involve the joining of a break to a sequence from the same chromosome. These intrachromosomal translocations are not seen recurrently in cancer cells. This suggests that many translocations do not contribute to tumorigenesis and that oncogenic translocations that increase cell survival and proliferation are selected for during the evolution of a tumour.
As the frequency of double-strand breaks at a particular genomic site seems to be the key determinant of whether that site becomes involved in a translocation, it is important to understand the processes that produce double-strand breaks. DNA replication is a source of DNA double-strand breaks 97 : as the entire genome is replicated during cell division, any genomic site is a potential site for replication-associated double strand breaks. However, replication-associated DNA damage is not entirely random. Common fragile sites (CFSs) are regions of the genome that are prone to breakage during replication stress. Whereas CFSs are relatively stable in normal cells, cancer cells accumulate breaks and genomic aberrations, including translocations, at these sites 98, 99 . Breakage at CFSs in cancer cells seems to be a consequence of replication stress arising from accelerated, oncogene-mediated replication [100] [101] [102] [103] [104] . In addition to CFSs, a second class of genomic sites that are prone to double-strand breakage and are associated with translocations in human cancer has recently been identified in murine B cells 105 . These early replicating fragile sites (ERFSs) were identified using ChIP followed by deep sequencing to reveal sites that are preferentially bound by DNA damage response proteins after replication stress. ERFSs are distinct from CFSs because they are found around early replication origins, whereas CFSs replicate late in S phase. ERFSs also have a high GC content, are commonly associated with repetitive DNA elements and correlate with transcriptionally active genes in an open chromatin environment. Breakage at ERFSs is AID independent, hence these sites may also be present in other cell types. Some euchromatic regions are targets of both AID activity in G1 and ERFS fork collapse during S phase; however, whereas AID activity is limited to 1-2 kb of promoters, breakages at ERFSs span a much larger region ranging from 10 kb to 1,000 kb 105 . Chromatin and transcriptional status are likely to play a substantial part in determining the likelihood that a particular genomic site will be involved in a translocation. A correlation of translocations with transcriptional activity was noted from deep-sequencing studies 6, 7 , and transcription has been reported to predispose genomic fragile sites to DNA breakage by causing increased Figure 5 | Regulation of DNA double-strand break repair pathways. Non-homologous end-joining mediated by Ku70 and Ku80 is favoured in G1 phase, when the activities of BRCA1 and CtBP-interacting protein (CtIP) are repressed by a complex of p53-binding protein 1 (53BP1), Pax transactivation domain-interacting protein (PTIP) and RAP1-interacting factor 1 (RIF1), which coats the chromatin in the vicinity of double-strand breaks. During the transition to S/G2 phase, BRCA1 acquires the ability to bind at break sites, where it promotes loading of repair factors either by direct displacement of the 53BP1 complex or by remodelling of the chromatin environment at the DNA break. The mechanism for BRCA1 activation and recruitment is still unknown. Also during S/G2 phase activation by cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation (P) allows CtIP to become active at the break site, where it resects duplex DNA to form a 5ʹ single-strand overhang. This favours resection-dependent repair pathways, including alternative end-joining and homologous recombination. Commitment to homologous recombination is mediated by loading of replication protein A (RPA) and RAD51 at the single-stranded DNA region formed by resection at the DNA break site.
collapse of DNA replication forks 106 . Although the existing data indicate that transcriptionally active regions are more prone to translocations, γH2AX, which signals DNA damage, accumulates more readily in euchromatic sites than in heterochromatin 107, 108 . Double-strand breaks also take longer to repair when located in heterochromatin 109 . Heterochromatin protein 1α (HP1α; also known as CBX5) paralogues are recruited to break sites [110] [111] [112] , and depletion of HP1α or of the nucleosome assembly complex component chromatin assembly factor 1 (CAF1) inhibits repair by homologous recombination 113 .
Translational opportunities and perspectives
Sequencing-based approaches have enabled considerable progress in recent years in understanding the nature and effect of chromosome translocations. We now have a much clearer idea of the frequency and complexity of translocations. Although translocations are almost invariably found when we study the genomic landscape of cancer cells, the importance of translocations to the onset of malignancy is still a matter of debate. In contrast to the situation with the characteristic clonal translocations identified in CML and Burkitt's lymphoma, many translocations do not seem to be primary drivers of cancer cell growth. We are still at an early stage in analysing the sequencing data that are pouring in, and making sense of how translocations influence cancer cell growth will be a major topic of research interest in the coming years. Another major challenge lies in understanding the cell ular pathways that underpin the genomic complexity of cancer cells. What pathways are responsible for causing translocations? Is there a role for replication-based mechanisms in the formation of translocations, and what is the importance of microhomology at translocation junctions? Answering these questions will require us to build on our current understanding of the genes involved in translocation pathways, enabling us to test requirements for the appearance of translocations in vivo. Sequencing is demonstrating that many translocations are more complex than we had previously imagined 65 . It will be interesting to see whether chromothrypsis 2 arises by different pathways to translocations or whether it merely represents the most extreme end of a range of chromosome rearrangements present in cancer cells.
Although we have made major progress in understanding nuclear phenomena that influence the frequency of translocations, there are clearly remaining issues to address relating to the effect of chromatin on genomic instability and translocation frequency. At the time of writing, there has been no published, genomewide attempt to correlate chromatin status with translocation frequency. Such work would shed light on several interesting studies that have demonstrated how chromatin can affect the processing of DNA breaks. Future work is also likely to identify other factors in mammalian cells which, as is the case with 53BP1, PTIP, RIF1, Ku and DNA-PKcs, are able to modulate the use of NHEJ pathways. The activity of such factors could determine the frequency of translocations by biasing the repair of DNA breaks to error-prone end-joining pathways.
As translocations seem to be mainly produced by the C-NHEJ and A-EJ pathways, selective inhibition of end-joining pathways could potentially be used to prevent the appearance of cancer or to block the appearance of further mutations that drive cancer growth and survival. Global inhibition of end-joining is unlikely to be a beneficial long-term treatment modality on the basis of observations in gene-targeted mice that correlate loss of end-joining activity with increased chromosome abnormalities and tumour incidence. Nonetheless, cancer cells seem to make use of A-EJ pathways to join DNA double-strand breaks in aberrant ways that promote cancer growth 114 . Acquired resistance of BRCA2-deficient cells to poly(ADP-ribose) polymerase (PARP) inhibition has been shown to occur by A-EJ-mediated internal deletions within the BRCA2 gene that restore its activity 115, 116 . These observations reinforce the importance of understanding the genetic requirements of A-EJ to enable specific targeting of this pathway.
Inhibitors of DNA ligases have been identified and shown to be toxic towards cancer cell lines and to synergize with methyl methanesulphonate treatment to increase cell killing 117, 118 . Inhibitors of DNA-PKcs have likewise shown promise, potentially on the basis of their ability to bias DNA repair towards homologous recombination instead of more toxic pathways 119 . Although animal studies are currently lacking, in the future agents that enable repair to be shifted from mutagenic pathways towards repair pathways that promote faithful DNA repair (as has been proposed for inhibition of 53BP1 in patients with BRCA1 deficiency 34 ) could provide a new avenue for cancer treatment that is based on the prevention of mutation.
